On Wednesday, in the course of Afternoon trade, Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), dropped -0.62%, and is now trading at $10.43.
Ironwood Pharmaceuticals, declared positive top-line data from a Phase I study of IW-1973, its lead investigational soluble guanylate cyclase (sGC) stimulator. In the study, IW-1973 demonstrated cardiovascular pharmacodynamic effects, extensive tissue distribution, proof of mechanism for sGC stimulation, and a dose range that was well tolerated in healthy volunteers. The totality of clinical and preclinical data generated to date strongly support continued development of IW-1973 as a potential once-daily oral therapy.
Ironwood intends to initiate a Phase Ib multiple ascending dose study of IW-1973 in the fourth quarter of 2015. This study will inform the selection of doses and precedingity indications for the Phase II program, which will focus on areas with the highest unmet need and optimal path to market. Ironwood intends to initiate at least two Phase II proof of concept studies for IW-1973 in 2016.
Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union.
During an Afternoon trade, Shares of Colfax Corp (NYSE:CFX), dipped -0.44%, and is now trading at $38.44.
Colfax Corporation, declared that Matthew L. Trerotola, formerly an Executive Vice President at DuPont, has been named Chief Executive Officer and a Director of Colfax, effective July 24, 2015. He succeeds Steven E. Simms, who will assist in the transition and will continue to serve on the Colfax Board. Mr. Simms notified the Board early this year that he planned to retire, and the Board subsequently undertook a search for a replacement.
Mr. Trerotola, 48, has spent most of his career at DuPont, Danaher Corporation, and McKinsey & Company. He was most recently an Executive Vice President and a member of DuPont’s Office of the Chief Executive, responsible for DuPont’s $6.3 billion Electronics & Communications and Safety & Protection segments. He also had corporate responsibility for DuPont’s Asia-Pacific business. Many of his roles at DuPont involved applying innovation to improve margins and accelerate organic growth in global businesses. Preceding to rejoining DuPont in 2013, Mr. Trerotola had served in leadership roles at Danaher since 2007, and was most recently Vice President and Group Executive for Life Sciences, which is comprised of four companies with about 7,000 associates and $2.5 billion in revenue. Formerly, he was Group Executive for Product Identification from 2009 to 2012, and President of the Videojet business from 2007 to 2009. While at McKinsey & Company from 1995 to 1999, he focused primarily on assisting industrial companies accelerate growth.
Colfax Corporation, an industrial manufacturing and engineering company, provides gas-and fluid-handling, and fabrication technology products and services to commercial and governmental customers worldwide.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), during its Wednesday’s current trading session fell -1.86%, and is now trading at $125.92.
Vertex Pharmaceuticals Incorporated, declared that the U.S. Food and Drug Administration (FDA) approved ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people ages 12 and older with two copies of the F508del mutation. It is only indicated for these patients, who can be identified with a genetic test.
Cystic fibrosis is a rare, life-threatening genetic disease. People with two copies of the F508del mutation represent the largest group of people with CF. Of the 30,000 people in the United States with CF, about 8,500 ages 12 and older have two copies of the F508del mutation. ORKAMBI will be accessible for shipment to specialty pharmacies in the United States within days.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs.
Finally, Ameren Corp (NYSE:AEE), gained 0.69% at $ 39.65.
Ameren Illinois customers are experiencing fewer and shorter power outages as a result of electric grid upgrades the company has implemented under the state’s Energy Infrastructure Modernization Act (EIMA). These reliability improvements are saving its customers an estimated $48 million each year.
Since the modernization program began in 2012, the installation of storm-resilient utility poles, automated switches, and an upgraded distribution grid have resulted in 238,000 fewer annual electricity service interruptions on average. And when customers do experience an outage, Ameren Illinois is restoring power 19 percent faster on average than in previous years.
Ameren Corporation operates as a public utility holding company in the United States. The company engages in the rate-regulated electric generation, transmission, and distribution; and rate-regulated natural gas transmission and distribution businesses.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
